Cargando…
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
Recent data suggest that expression of the membrane P(170)-glycoprotein (P-gp) may confer resistance to the topoisomerase- I-interactive agent topotecan. The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on P-gp-mediated resistance to topotecan in human br...
Autores principales: | Vanhoefer, U, Müller, M R, Hilger, R A, Lindtner, B, Klaassen, U, Schleucher, N, Rustum, Y M, Seeber, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362978/ https://www.ncbi.nlm.nih.gov/pubmed/10604726 http://dx.doi.org/10.1038/sj.bjc.6694384 |
Ejemplares similares
-
Potentiation of the Vincristine Effect on P388 Mouse Leukemia Cells by a Newly Synthesized Dihydropyridine Analogue, PAK‐200
por: Shudo, Norimasa, et al.
Publicado: (1992) -
Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996) -
Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999) -
A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001) -
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)